We use chemical creativity to tackle hard biology questions, target the “undruggable”, & train the next generation. Part of @DanaFarber research universe.
🎙️ The Target 2035 podcast series is officially LIVE!
In our pilot episode, meet our hosts - @MilkaKostic, @LabScribbles and Opher Gileadi who share their personal motivations for joining the Target 2035 initiative.
Tune in to the pilot episode now! podcasters.spotify.com/pod/s… 🎧
Very excited for our next seminar this Thursday:
Derek Bartlett (formerly @pfizer, now @UNC) will share insights on PK-PD modelling for TPD and Kyle Mangano (@Amgen) will present how VIPER-TACs co-opt viral E3s.
👉Join us at 12 PM EST/ 6 pm CET (back to original schedule)!
An absolute pleasure to be able to contribute to this book with the amazing @JunQiLab, and brilliant Qi Liu and Aimee Qi. From @RoySocChem, “Epigenetic Drug Discovery.” We specifically focus on targeting histone acetyltransferases, and new chemical strategies to target them.
New studies from our lab published in @CellChemBiol designing anti-diabetic metabolic routes using novel small molecules (SR-18292) that re-direct lactate and gluconeogenic carbon substrates to mitochondrial oxidation cell.com/cell-chemical-biolo…
Xin Zhou, PhD, a researcher at Dana-Farber and her team have developed a new platform that repurposes a cancer cell's own refueling mechanism to degrade proteins driving tumor growth. This breakthrough could reshape how we approach cancer treatment. blog.dana-farber.org/insight…
Thanks to the wonderful team at @DanaFarber Communications, @DFCI_ChemBio Program has a new website! I am especially proud of our Careers page that includes a link to an onboarding document for incoming techs, postdocs and students! dana-farber.org/research/int…
We are excited to share our lab’s first research article! rdcu.be/dU5AC We have developed Transferrin Receptor Targeting Chimeras (TransTACs), a novel class of heterobispecific antibodies designed for targeted degradation of membrane proteins. nature.com/articles/s41586-0…
Now in @Nature: work from @xinzhoulab on developing TransTACs, a new platform for degrading membrane proteins with many different applications like reversible control of CAR-T.
nature.com/articles/s41586-0…
Congratulations to the entire @xinzhoulab in collaboration with the Pasi lab on this new manuscript! Thank you Xin for letting me support this incredible project. Honored and grateful to have been a part it! #SiSePuede
Excited to kick off our post-summer series! This Thursday we are hosting @gpsapkota sharing insights on redirecting phosphatase through induced proximity.
**Important: The time has changed to 12 PM EST!
Becoming the editor of Chemistry & Biology and relaunching it into Cell Chemical Biology (@CellChemBiol) in 2016 were FUN! BUT: interacting with thousands of scientists from across the globe was... PRICELESS!
With gratitude, Milka
sciencedirect.com/science/ar…
Hear from @nickpolizzi_ about how AI can optimize protein-ligand interactions at #MoML2024 on Nov. 5! Early Bird tickets are still available until Oct. 4!
🐦 Register now: moml.mit.edu
ALT Graphic with text that reads "Ligand-aware protein design using reinforcement learning"
Bolded text beneath reads "Nicholas Polizzi, PhD Assistant Professor Harvard Medical School"
Regular smaller text beneath reads "November 5, 2024 MoML @ MIT"
The right side features a headshot of Nicholas Polizzi.
Next year, HMS will welcome its first class of students to a new master’s program (MMSc in Therapeutic Sciences). Preparing students for careers focused on early drug discovery that translates to new medicines has long been a core goal of the HMS Therapeutics Initiative. bit.ly/3ZpvXHz
This week is postdoc appreciation week!! Thanks to all our awesome postdocs for fueling discovery in @DFCI_CancerBio labs!! Hope you enjoy this week's events organized by @DFCI_PGA
Interesting talk by Samantha Bevill @DFCI_ChemBio at #TPDWebinar. She talked about her research into developing tumor-specific PROTACs on the example of engaging the E3 ubiquitin ligase MDM2 to specifically degrade proteins in MDM2-amplified cancer cells. cell.com/cell-genomics/fullt…
We are excited to be hosting Christopher D. Lima, PhD (@MSKCancerCenter / @HHMINEWS investigator) as a speaker in our Chemical Biology Seminar Series. Great way to kick off 2024/25 season of science and sharing!